Control of HIV despite the Discontinuation of Antiretroviral Therapy
about
Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adultsStructured treatment interruptions (STI) in chronic suppressed HIV infection in adultsStimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionReconsidering early HIV treatment and supervised treatment interruptionsLimited durability of viral control following treated acute HIV infectionAnalysis of successful immune responses in persons infected with hepatitis C virusDrug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory TrialProfound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionBarriers to HIV Cure.DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruptionAntiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatmentNeutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells.The role of antigen-independent persistence of memory cytotoxic T lymphocytes.MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.HIV preferentially infects HIV-specific CD4+ T cells.Vaccines for the control of HIV/AIDS.CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatmentHuman immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.How a single patient influenced HIV research--15-year follow-up.DNA vaccines: future strategies and relevance to intracellular pathogens.Cytokine therapy or structured treatment interruptions in HIV infection: which is best?Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI SubstudyExploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunizationAcute HIV revisited: new opportunities for treatment and prevention.Evaluating therapeutic vaccines in patients infected with HIV.Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity.Structured therapy interruption (STI) and deceptive imprinting.Structured treatment interruptions in HIV infection: benefit or disappointment?Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection.
P2860
Q24245541-34063C9A-CC5B-43B9-80ED-556535D6CCD3Q24245709-16C9E711-F107-4AA4-8969-FBEA9E2FBC99Q24536249-44B8C3E9-237F-47BD-92CF-45A03822DF0EQ24796745-539312BC-AED2-45AB-A5BE-25E6C5952E20Q24804986-A910FD14-E826-4ED7-9DD2-827566D7C199Q27860698-5F764680-A8FD-4E9C-A4FE-FB604876F6E3Q28552171-4E124157-27A2-4218-9BC4-9407C03CA9D5Q28748901-EEDE1996-8A08-46FF-9218-D49E148EF4E2Q30245414-CD938A6C-F708-405B-97F7-CD1C159F7855Q30408029-65CA2E59-DFCE-41C6-9BF7-0F0E3FA7CAE7Q33654409-18100888-F3B3-479E-A9BD-124464DD49CEQ33745356-09EEDD5C-6073-468E-BE0F-56966EF0F76DQ33797315-F6F866E9-3A9B-46A1-B74C-671A1F01B8D7Q33799700-F500FCE7-9B0E-4ABD-80DD-3DE84E340BE0Q33847697-C83D09EF-9F7A-4E67-9A78-320340C36966Q33852947-52B86A6D-BB10-4199-9A5C-300F3C5453A8Q33879538-AF12024E-5B90-4470-A329-558F1827C33EQ33936926-0BC5D812-17A4-4D0A-A002-85DC41BAA0B7Q33949316-B95DC2F4-5F04-40C7-BFE3-E9ADC913429FQ33958893-CC76D7A9-B2FE-4A77-AA47-EC161045522FQ34017996-BF6B8485-CFDA-494E-A79D-583FDB7BB354Q34057778-0F506B6D-AF61-4824-9C0B-CEF17D94D59CQ34143960-24B88C84-5925-456D-9B37-A585F42B1CCAQ34255654-CF62B004-1251-4691-B95E-2C29C6337116Q34403835-FA7F6062-6394-4B88-8B7E-D861ED2121AFQ34570728-9B1A0785-73E8-4AEF-99F9-70018A57E129Q34660778-0302B053-AB61-4843-BE38-70E7E812C0D8Q34716901-DBBAAB09-B36B-4933-A22C-1B2D4E9A47A7Q34730855-28B22557-D89E-4B75-8EAA-C5DA0F003DADQ34869927-1862301E-75F1-47EA-B9C4-BDCC37135BFDQ35159818-7D9F8E23-422E-42BD-9A87-4853E7CDFE87Q35207318-FFAC29D0-4C34-4B05-9752-53D9228426F2Q35635412-E11F0FB2-8CA2-4EBB-92D6-EC95902FB502Q35730339-8757CAD9-1B6C-4419-941C-061736CC9301Q35851820-3A13767C-7393-4CDC-8280-8FCD39EAF25FQ35862206-8AEFBE01-F259-4DA2-B752-8B1CAAEDC4ECQ35865986-CDCB29C9-D8FC-431E-924F-826FF7591A11Q35888741-E52BA0AD-DB7B-48B3-ABE2-541A238B14ADQ35917152-614218B4-AAEE-4744-87B2-7B22DDAE1AA2Q36026242-D95CE568-64EC-44DE-9908-A3D0CDAC1C58
P2860
Control of HIV despite the Discontinuation of Antiretroviral Therapy
description
article
@en
im Mai 1999 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 1999
@uk
name
Control of HIV despite the Discontinuation of Antiretroviral Therapy
@en
Control of HIV despite the Discontinuation of Antiretroviral Therapy
@nl
type
label
Control of HIV despite the Discontinuation of Antiretroviral Therapy
@en
Control of HIV despite the Discontinuation of Antiretroviral Therapy
@nl
prefLabel
Control of HIV despite the Discontinuation of Antiretroviral Therapy
@en
Control of HIV despite the Discontinuation of Antiretroviral Therapy
@nl
P2093
P50
P1476
Control of HIV despite the Discontinuation of Antiretroviral Therapy
@en
P2093
Eric Rosenberg
Franco Lori
Heiko Jessen
Judy Lieberman
P304
P356
10.1056/NEJM199905273402114
P407
P577
1999-05-27T00:00:00Z